Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.
A AlgaziK P PapadopoulosF TsaiA R HansenN AngraM DasS ShethL L Siu
Published in: ESMO open (2024)
Treatment was well tolerated. However, response rates were low despite target engagement, no drug-drug interactions, and no drug-neutralizing antibodies to durvalumab.